Et studie af ABBV-295 subkutane injektioner for at vurdere bivirkninger og farmakokinetik hos voksne deltagere med fedme
En fase 1b-undersøgelse til vurdering af sikkerhed, tolerabilitet, farmakokinetik, immunogenicitet og farmakodynamik ved flere subkutane doser af ABBV-295 hos voksne forsøgspersoner med fedme
This study is to assess adverse events, change in body weight and pharmacokinetics in adult participants with obesity receiving ABBV-295 subcutaneous injections or matching placebo.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
California
-
Anaheim, California, Forenede Stater, 92801
- CenExel Act- Anaheim Clinical Trials /ID# 283200
-
-
Illinois
-
Grayslake, Illinois, Forenede Stater, 60030
- Acpru /Id# 278624
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- BMI ≥ 30.0 to ≤ 45.0 kg/m2 after rounding to the tenths decimal at Screening (BMI is calculated as weight in kg divided by the square of height measured in meters) with or without weight related stable comorbidities (e.g., hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease).
- A female who is not pregnant or breastfeeding and is not considering becoming pregnant or donating eggs during the study or for approximately 60 days after the last dose of study treatment.
Exclusion Criteria:
- Participant has a self-reported change in body weight ≥ 5% within 3 months prior to Screening.
- HbA1c ≥ 6.5% and/or serum glucose ≥ 126 mg/dL at Screening.
- Participant has taken a medication for the purpose of treating obesity or has been enrolled in an obesity trial within 180 days prior to study treatment administration.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Tredobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: ABBV-295 or Placebo-Group 1
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks. |
Subcutaneous Injections Subcutaneous Injections |
|
Eksperimentel: ABBV-295 or Placebo-Group 2
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks. |
Subcutaneous Injections Subcutaneous Injections |
|
Eksperimentel: ABBV-295 or Placebo-Group 3
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks. |
Subcutaneous Injections Subcutaneous Injections |
|
Eksperimentel: ABBV-295 or Placebo-Group 3 Extension
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks or 20 weeks. |
Subcutaneous Injections Subcutaneous Injections |
|
Eksperimentel: ABBV-295 or Placebo-Group 4
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks. |
Subcutaneous Injections Subcutaneous Injections |
|
Eksperimentel: ABBV-295 or Placebo-Group 4 Extension
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks or 20 weeks. |
Subcutaneous Injections Subcutaneous Injections |
|
Eksperimentel: ABBV-295 or Placebo-Group 5
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 20 weeks. |
Subcutaneous Injections Subcutaneous Injections |
|
Eksperimentel: ABBV-295 or Placebo-Group 6
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 20 weeks. |
Subcutaneous Injections Subcutaneous Injections |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants with Adverse Events (AEs)
Tidsramme: Up to approximately 194 days
|
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. |
Up to approximately 194 days
|
|
Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements
Tidsramme: Up to approximately 194 days
|
Number of participants with abnormal change from baseline in vital sign measurements like heart rate, systolic and diastolic blood pressure will be assessed. |
Up to approximately 194 days
|
|
Number of Participants with Change from Baseline in Electrocardiogram (ECG)
Tidsramme: Up to approximately 194 days
|
12-lead resting ECG will be recorded. |
Up to approximately 194 days
|
|
Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed
Tidsramme: Up to approximately 194 days
|
Number of participants with abnormal change in clinical laboratory test results like biochemistry, hematology will be assessed. |
Up to approximately 194 days
|
|
Maximum Observed Plasma Concentration (Cmax) of ABBV-295
Tidsramme: Up to approximately 194 days
|
Cmax of ABBV-295 |
Up to approximately 194 days
|
|
Time to Cmax (Tmax) of ABBV-295
Tidsramme: Up to approximately 194 days
|
Tmax of ABBV-295 |
Up to approximately 194 days
|
|
Trough plasma concentration (Ctrough) of ABBV-295
Tidsramme: Up to approximately 194 days
|
Ctrough of ABBV-295 |
Up to approximately 194 days
|
|
Apparent terminal phase elimination rate constant (BETA) of ABBV-295
Tidsramme: Up to approximately 194 days
|
BETA of ABBV-295 |
Up to approximately 194 days
|
|
Terminal phase elimination half-life (t1/2) of ABBV-295
Tidsramme: Up to approximately 194 days
|
t1/2 of ABBV-295 |
Up to approximately 194 days
|
|
Area under the plasma concentration-time curve (AUC) of ABBV-295
Tidsramme: Up to approximately 194 days
|
AUC of ABBV-295 |
Up to approximately 194 days
|
|
Area under the plasma concentration-time curve over the dosing interval (AUCtau) of ABBV-295
Tidsramme: Up to approximately 194 days
|
AUCtau of ABBV-295 |
Up to approximately 194 days
|
|
Dose Normalized Cmax of ABBV-295
Tidsramme: Up to approximately 194 days
|
Dose normalized Cmax of ABBV-295 will be assessed. |
Up to approximately 194 days
|
|
Dose Normalized AUC of ABBV-295
Tidsramme: Up to approximately 194 days
|
Dose normalized AUC of ABBV-295 will be assessed. |
Up to approximately 194 days
|
|
Incidence of Anti-Drug Antibodies (ADAs)
Tidsramme: Up to approximately 194 days
|
Incidence of ADAs will be assessed. |
Up to approximately 194 days
|
|
Percent Change in Body Weight From Baseline
Tidsramme: Up to approximately 194 days
|
Percent change in body weight (kg) will be assessed. |
Up to approximately 194 days
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: ABBVIE INC., AbbVie
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- M26-089
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .